MA28267A1 - Formulations orales d'agonistes du recepteur 5-ht, utilisations et methodes de traitement faisant intervenir celles-ci - Google Patents

Formulations orales d'agonistes du recepteur 5-ht, utilisations et methodes de traitement faisant intervenir celles-ci

Info

Publication number
MA28267A1
MA28267A1 MA28986A MA28986A MA28267A1 MA 28267 A1 MA28267 A1 MA 28267A1 MA 28986 A MA28986 A MA 28986A MA 28986 A MA28986 A MA 28986A MA 28267 A1 MA28267 A1 MA 28267A1
Authority
MA
Morocco
Prior art keywords
treatment
methods
same
receptor agonists
oral formulations
Prior art date
Application number
MA28986A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MA28267A1 publication Critical patent/MA28267A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une formulation orale acceptable sur le plan pharmaceutique qui comprend un matériau central comportant une dose efficace sur le plan thérapeutique d'un agoniste du récepteur 5-HT, ou un sel, un solvate ou un dérivé associé acceptable sur le plan pharmaceutique ; ledit matériau central étant pourvu d'un revêtement sensiblement résistant à l'eau qui comprend un ou plusieurs matériaux sensiblement résistants à l'eau.
MA28986A 2003-10-30 2006-04-28 Formulations orales d'agonistes du recepteur 5-ht, utilisations et methodes de traitement faisant intervenir celles-ci MA28267A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0325383A GB2407498B (en) 2003-10-30 2003-10-30 Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient

Publications (1)

Publication Number Publication Date
MA28267A1 true MA28267A1 (fr) 2006-11-01

Family

ID=29725668

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28986A MA28267A1 (fr) 2003-10-30 2006-04-28 Formulations orales d'agonistes du recepteur 5-ht, utilisations et methodes de traitement faisant intervenir celles-ci

Country Status (15)

Country Link
US (2) US20070077299A1 (fr)
EP (1) EP1682100A2 (fr)
JP (1) JP2007533652A (fr)
KR (1) KR20060109919A (fr)
CN (1) CN1901889A (fr)
AP (1) AP2006003613A0 (fr)
AU (1) AU2004287257B2 (fr)
BR (1) BRPI0415803A (fr)
CA (1) CA2544258A1 (fr)
GB (1) GB2407498B (fr)
IL (1) IL175303A0 (fr)
MA (1) MA28267A1 (fr)
MX (1) MXPA06004846A (fr)
WO (1) WO2005044222A2 (fr)
ZA (1) ZA200603438B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
CA2620491A1 (fr) * 2005-09-09 2007-03-15 Wyeth Formes dosifiees pharmaceutiques et compositions associees
CN101365450A (zh) * 2006-02-09 2009-02-11 特瓦制药工业有限公司 孟鲁司特钠的稳定药物制剂
ES2527448T3 (es) * 2008-04-28 2015-01-23 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
CN101757623B (zh) * 2008-10-09 2013-12-04 北京德众万全药物技术开发有限公司 一种5-ht受体激动剂固体药物组合物
JP6393274B2 (ja) 2012-12-19 2018-09-19 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 改良された許容性および良好な保存安定性を有する錠剤
US9511561B2 (en) * 2013-09-12 2016-12-06 R.R. Donnelley & Sons Company Multi-layer forms and methods of manufacturing the same
CN104739774A (zh) * 2013-12-26 2015-07-01 康普药业股份有限公司 一种琥珀酸舒马曲坦颗粒及其制备工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614020C2 (de) * 1976-04-01 1984-01-26 Knoll Ag, 6700 Ludwigshafen Verfahren zur Isolierung von Presslingen
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
JP2987813B2 (ja) * 1993-07-12 1999-12-06 住友製薬株式会社 ワックス被覆製剤およびその製法
JPH09216817A (ja) * 1996-02-08 1997-08-19 Amano Pharmaceut Co Ltd 防湿性且つ易水崩壊性コーティング製剤
EP0999841B1 (fr) * 1997-07-03 2001-10-17 Pfizer Limited Compositions pharmaceutiques contenant l'hemisulfate d'eletriptane et de la cafeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
EP1064938A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à libération contrôlée avec au moins une impulsion temporelle
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
CA2446904A1 (fr) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Administration d'esters medicamenteux par inhalation
MXPA04006163A (es) * 2001-12-20 2004-11-01 Pharmacia Corp Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
BR0312795A (pt) * 2002-07-19 2005-05-10 Ranbaxy Lab Ltd Apresentação farmacêutica de sumatriptan, processo para sua preparação e método para tratar a enxaqueca
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient

Also Published As

Publication number Publication date
IL175303A0 (en) 2006-09-05
AU2004287257A2 (en) 2005-05-19
AP2006003613A0 (en) 2006-06-30
MXPA06004846A (es) 2006-07-06
KR20060109919A (ko) 2006-10-23
JP2007533652A (ja) 2007-11-22
GB0325383D0 (en) 2003-12-03
CN1901889A (zh) 2007-01-24
BRPI0415803A (pt) 2006-12-26
GB2407498A (en) 2005-05-04
EP1682100A2 (fr) 2006-07-26
WO2005044222A3 (fr) 2006-01-12
AU2004287257A1 (en) 2005-05-19
AU2004287257B2 (en) 2011-04-14
GB2407498B (en) 2008-06-11
US20110008412A1 (en) 2011-01-13
US20070077299A1 (en) 2007-04-05
WO2005044222A2 (fr) 2005-05-19
ZA200603438B (en) 2008-01-30
CA2544258A1 (fr) 2005-05-19

Similar Documents

Publication Publication Date Title
MA28267A1 (fr) Formulations orales d'agonistes du recepteur 5-ht, utilisations et methodes de traitement faisant intervenir celles-ci
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
DK0850050T3 (da) Orale hurtigt-opløsende sammensætninger for dopaminagonister
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
DZ3484A1 (fr) Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda
PT1041987E (pt) Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
EA200501586A1 (ru) Фармацевтические продукты
BR0318456A (pt) tablete de hidrocloreto de bupropion com liberação modificada
BRPI0413719A (pt) agonistas alfa2 não-sedativos
EE200300524A (et) Ühendid, mis on CB2-retseptori agonistid, neid sisaldavad ravimkoostised ja nimetatud ühendite kasutamine ravis
CY1112517T1 (el) Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης
DE69937994D1 (de) Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
NO20004215D0 (no) Et farmasøytisk preparat som omfatter en angiotensin II type 2-reseptoragonist, og anvendelse derav
CY1106072T1 (el) Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
NO336061B1 (no) Farmasøytisk blanding samt anvendelse av et anti-interleukin-6 reseptor antistoff
CY1110260T1 (el) Στερεες φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν εναν αγωνιστη υποδοχεα s1p και μια αλκοολη σακχαρων
PL1797871T3 (pl) Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania
BRPI0413676A (pt) composto, e, composição farmacêutica
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
NO20026103L (no) 1-amino-alkylcycloheksaner som 5-HT3 og neuronale nikotinreseptorantagonister
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
EA200100089A1 (ru) Предотвращение рецидива мигрени